Patent Grant
7629384
1. Field of the Invention
This invention relates to topical application of a cream, gel, or other vehicle which contains substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed and overcoming erectile dysfunction, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply.
2. Prior Art
Approaches to improving local blood flow have been many and consist of both systemic and topical approaches. Many beneficial effects could be obtained should improvement in local blood flow be achieved since impairment of local blood flow causes a variety of negative consequences.
It has been recognized that deficiencies in blood flow in the scalp occur in male pattern baldness. See G. Duplecnain et al., J. Louisiana State Med Soc. 146, 7 (1994); P Klemp et al., J Invests Dermatol 95, 725 (1989); S Toshitani et al., J Dermatol 17, 240 (1990). Topical minoxidil has been used as an agent for hair growth in male pattern baldness with varying results. Though the suggestion has been made that minoxidil operates through increase in the blood supply to the scalp, many investigators have failed to show such an effect. See E de Boer et al., Acta Dermato-Venereoligica 68, 271 (1988); C Bunker et al., British J Derm 117, 668 (1987).
It has long been recognized that impaired blood flow to the penis is a major cause of erectile failure (impotence) in men. See A Moradian et al. Am J. Med 85, 748, (1988); T Hwang et al. J Formosan Med Assoc 89, 992 (1990). Further it has been recognized by using isolated tissue in vitro and in animal experiments that nitric oxide is an important mediator of relaxation of the vessels in penile cavernous tissue. See H Kirkeby et al. Acta Physiol Scand 149, 385 (1993). Topical nitroglycerine has been used in the treatment of impotence because of its ability to dilate vessels. The results were inconclusive and the treatment not well tolerated because of the cardiac response to nitroglycerine. See S Negelev J Urology 143, 586 (1990).
Accordingly, several objects and advantages of the instant invention are to induce the growth of hair on portions of human scalp which has insufficient hairby means of enhancement of the body's natural mechanisms. It is yet another object of the instant invention to induce healing of superficial ulcers of the limbs by means of enhancement of the body's natural mechanisms. It is still another object of the instant invention to overcome erectile failure restoring natural male sexual function by means of enhancement of the body's own natural mechanisms.
It was discovered that topical application of a nitric oxide precursor, L-arginine, in its various forms contained in a variety of topical preparations, either by themselves or with other agents to aid in penetration, such as a high ionic strength environment, neutralization of its charge in a complex or by other means, or included in a liposome or other biological carrier, when administered to the scalp causes hair growth, when administered to superficial ulcers causes healing and when administered to the penis enhances erectile function. Increasing the levels of concentration of penetrants in combination with reduced amounts of L-arginine maintains effective treatment concentrations.
In one embodiment of the invention, a penetrating cream containing L-arginine at an effective concentration and a salt, such as sodium chloride, at a concentration sufficient to create a hostile biophysical environment for the L-arginine in the cream is applied to nightly to the scalp containing a deficit of hair induces hair growth within 3-4 months.
Further, in accordance with this invention, a penetrating cream containing L-arginine in a concentration sufficient to produce the desired effect along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment when applied to the penis induces firm and natural erections within 20 minutes.
Consequently, with the discovery of the present invention, a means to restore hair growth on a portion of scalp scarce in hair has been found. Further, with the discovery of the present invention, a means to heal superficial ulcers has been found. Additionally, with the discovery of the present invention, a means to overcome erectile dysfunction has been found.
In preferred embodiments, the delivery vehicle is a penetrating cream, the L-arginine is present as L-arginine hydrochloride in a concentration sufficient to produce the desired effect and the agent which creates the hostile biophysical environment is sodium chloride at a concentration sufficient to aid in tissue absorption. L-arginine or its derivatives are present in a concentration of 1% to 35%, with preferred concentrations 5% to 35%, and 12% to 35% better. These and other objects and features of the present invention will become apparent to those skilled in the art from reading the description of the invention, which follows.
The preferred embodiment consists of a base cream with the properties of excellent absorption into the skin which also contains L-arginine hydrochloride (12.5% w/v), choline chloride (10%), sodium chloride (5% w/v)and magnesium chloride (5% w/v). The components of the base cream may be those commonly found in hand creams, such as water, mineral oil, glyceryl stereate, squalene, propylene glycol stearate, wheat germ oil, glyceryl stearate, isopropyl myristate, steryl stearate, polysorbate 60, propylene glycol, oleic acid, tocopherol acetate, collagen, sorbitan stearate, vitamin A & D, triethanolamine, methylparaben, aloe vera extract, imidazolidinyl urea, propylparaben, and BHA. L-arginine hydrochloride provides a precursor to the molecule, nitric oxide, NO. Nitric oxide is the substance that relaxes the blood vessels, allowing for increased blood flow. Choline chloride, sodium chloride and magnesium chloride provides a high ionic strength environment for the highly charged molecule, L-arginine. This high ionic strength environment is an example of a hostile biophysical environment for L-arginine. That is, the highly charged ionic strength is an unfavorable environment for the highly charged L-arginine making the L-arginine anxious to move to a more hospitable, less charged environment such as human tissue. The base cream containing L-arginine, choline chloride, sodium chloride and magnesium chloride is the agent which produces beneficial effects such as hair growth, healing of ulcers such as leg ulcers or restoration of normal erectile function in males suffering from erectile dysfunction.
The cream acts effectively to induce hair growth on human scalp lacking sufficient hair when applied nightly to the bald area each night for several months. Hair growth is naturally a slow process. However, substantial hair growth is achieved over large areas of scalp with results becoming evident in a few weeks and substantial within several months. Yet further, the cream acts to promote healing of superficial ulcers such as those sometimes found on the legs of persons with severe diabetes. Application twice daily for a period of two weeks causes substantial healing and in many cases complete healing is achieved within this time period or slightly longer (3-4 weeks). Still further, the cream acts to overcome erectile dysfunction in males causing restoration of natural sexual function. These applications and others share as a common mechanism of action, improvement in local blood flow.
In one embodiment, the topical delivery vehicle of the present invention comprises:
L-arginine hydrochloride at a concentration of 0.25% to 25% by weight,
wherein the L-arginine hydrochloride is contained in a package selected from the group consisting of liposomes, emulsions of collagen, collagen peptides and combinations thereof,
wherein the delivery vehicle further comprises an ion donor selected from the group consisting of sodium chloride, choline chloride, potassium chloride, lithium chloride and magnesium chloride and mixtures thereof, and said ion donor is present in an amount sufficient to create a high ionic strength environment able to cause the L-arginine hydrochloride to migrate from the delivery vehicle to the skin where the delivery vehicle is applied,
wherein (i) said ion donor concentration in the delivery vehicle is 10% to 90% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is 0.25% to below 5% by weight, (ii) said ion donor concentration in the delivery vehicle is 5% to 80% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is 5% to 15% by weight, and (iii) said ion donor concentration in the delivery vehicle is 5% to 50% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is greater than 15% to 25% by weight.
Other Active Agents
While L-arginine hydrochloride is the preferred active agent because it is the agent in nature itself, it is non-toxic, is highly soluble and it is inexpensive, other agents could be used which are also precursors or donors of nitric oxide. These include D,L -arginine, L-arginine, alkyl (ethyl, methyl, propyl, isopropyl, butyl, isobutyl, t-butyl) esters of L-arginine and salts thereof. Pharmaceutically acceptable salts include hydrochloride, glutamate, butyrate, and glycolate. L-arginine concentrations desired are 1% to 35%, with 5% to 35% more effective with 12% to 35% best.
In the case of an alternative active agent were used it would be simply substituted for L-arginine in a delivery preparation and the preparation used as in the case of the L-arginine preparation.
Other Means of Effecting or Improving Absorption
A variety of means for effecting or improving absorption of the active agent can be envisioned. One principle behind the absorption of a highly charged molecule such as L-arginine into tissue is to either create a biophysically hostile environment in the delivery vehicle such that L-arginine would prefer to be in tissue, or to package L-arginine in such a way that it is carried into tissue or neutralize its charge by derivitization or forming a neutral salt. Examples of biophysically hostile environments, include but are not limited to; high ionic strength by the addition of ionic salts such as sodium chloride, magnesium chloride or choline chloride; high or low pH by adding pharmaceutically acceptable acids or bases; and highly hydrophobic environments by decreasing water content and increasing lipid, oil and/or wax content. Examples of packaging which would be carried into tissue includes liposomes or emulsions of collagen, collagen peptides or other components of skin or basement membrane. Examples of neutralization of charge include delivery of the active agent in the form or an ester or salt such as arginine glutamate which is electronically neutral.
In each case of creating a hostile biophysical environment for the active agent, the agent was added to an appropriate preparation. In the case of creating a high ionic strength ions such as but not limited to sodium chloride, potassium chloride, choline chloride, magnesium chloride, lithium chloride, alone or in combination were added in high concentration. Other highly charged molecules such as polylysine, polyglutamine, polyaspartate or copolymers of such charged amino acids may be used to create the hostile biophysical environment. Alternatively a hostile biophysical environment may be created by placing the highly charged L-arginine in an hydrophobic, oily environment such as in an oil-based cream containing little or no water. Absorption may further be aided by combining the use of hostile biophysical environments with the use of penetrating agents such as oleoresin capsicum or its constiutents or molecules containing heterocyclic rings to which are attached hydrocarbon chains.
In this example a 53 year old man with a scalp lacking sufficient hair consisting of a severely receding hairline as well as large “bald spot” on the top rear of his head was provided with a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v). The cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months the receding hairline (previously 4 cm of bald skin) had returned to normal and the “bald spot” previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with even this area showing some new hair growth.
In a 54 year old man with a history of impotence twice daily administration of a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (10% w/v) and magnesium chloride (5% w/v) directly to the penis twice daily for 7 days brought initial relief from the symptoms of impotence and allowed the subject to resume normal sexual activity. This relief of symptoms was maintained by continuation of the treatment daily.
In a 62 year old man with a history of impotence placed a condom containing a water based penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v) was warn on the flaccid penis for 30-60 minutes before erection was desired. At that time, when sexual performance was needed, an erection was easily obtained and normal sexual activity was conducted.
Accordingly, it can be seen that in the present invention I have provided agents, which when applied to scalp lacking sufficient hair causes hair growth through utilization of one of the body's own mechanisms. This effect is achieved by providing the biochemical substrate at the local site from which nitric oxide is produced. Nitric oxide causes increased local blood flow, which enables the growth of hair. Further I have provided agents which when applied to leg ulcers cause healing through use of the body's own mechanisms. Still further I have provided agents that when applied to a penis subject to erectile dysfunction causes restoration of normal sexual function. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide is produced. Nitric oxide causes increases in local blood flow allowing the body's own healing cells and substances to reach the ulcer site.
The treatments for hair loss, impotence and wound and ulcer healing discussed above can be performed with L-arginine or its derivatives without penetrants in a preferred concentration of 5% to 35%, with preferred concentrations greater than 10% with effectiveness greatest at concentration levels above 20%.
An effective concentration of L-arginine to produce the beneficial effects discussed herein can be reduced when a hostile biophysical environment is created which causes the L-arginine to cross the barrier of the skin. The skin barrier is harder to cross than the mucus membranes associated with the anus or inside the mouth or through the lower intestine when taken orally. Therefore to create an effective concentration of L-arginine a sufficient biophysical environment must be created corresponding to the concentration of L-arginine. With concentration of L-arginine or its derivatives below 5% to 0.25% it is desired to have a concentration of 10% to 90%, preferably from 25% to 75% of an ion donor such as a to create a high ionic strength environment.
With a concentration of 5% to 15% of L-arginine or its derivatives it is desired to have a concentration of 5% to 80%, preferably from 15% to 50% of an ion donor such as a to create a high ionic strength environment.
With a concentration of 15% to 25% of L-arginine or its derivatives it is desired to have a concentration of 5% to 50%, preferably from 10% to 30% of an ion donor such as a to create a high ionic strength environment.
A method of promoting hair growth, treating impotence or healing wounds comprising delivering a nitric oxide releasing substance selected from a member of the group consisting of L-arginine, L-arginine salts and L-arginine derivatives, to a selected area of the skin where hair growth is desired by topically applying to the selected area of skin where hair growth is desired a delivery vehicle for the substance, said delivery vehicle containing an effective amount of the substance, and a concentration of ionic salt sufficient to create a hostile biophysical environment which causes the substance to migrate from the delivery vehicle to the skin where the substance is absorbed by tissue wherein said delivery vehicle comprises water (20-80%), mineral oil (3-18%), glyceryl stearate (0.5-12%), squalene (0.2-12%), cetyl alcohol (0.1-11%), propylene glycol stearate (0.1-11%), wheat germ oil (0.1-6%), glyceryl stearate (0.1-6%), isopropyl myristate (0.1-6%), stearyl stearate (0.1-6%), polysorbate 60 (0.1-5%), propylene glycol (0.05-5%), tocopherol acetate (0.5-5%), collagen (0.05-5%), sorbitan stearate (0.05-5%), vitamin A&D (0.02%-4%), triethanolamine (0.01-4%), methylparaben (0.01-4%), aloe vera extract (0.01-4%), imidazolidinyl urea (0.01-4%), propylparaben (0.01-4%), bha (0.01-4%), L-arginine hydrochloride (5% to 25%), sodium chloride (5% to 25%), and magnesium chloride (5% to 25%) is applied to the selected area of skin where hair growth is desired.
This is a continuation in part of application Ser. No. 08/932,227 filed Sep. 17, 1997, the contents of which are incorporated by their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4681897 | Brand | Jul 1987 | A |
| 4702903 | Keefer | Oct 1987 | A |
| 4732892 | Sarpotdar et al. | Mar 1988 | A |
| 4871839 | Gibson | Oct 1989 | A |
| 4950654 | Horn et al. | Aug 1990 | A |
| 4976952 | Lang et al. | Dec 1990 | A |
| 5028435 | Katz et al. | Jul 1991 | A |
| 5180743 | Watanabe et al. | Jan 1993 | A |
| 5254331 | Mausner | Oct 1993 | A |
| 5332758 | Nakata et al. | Jul 1994 | A |
| 5391550 | Carniglia et al. | Feb 1995 | A |
| 5405919 | Keefer et al. | Apr 1995 | A |
| 5428070 | Cooke et al. | Jun 1995 | A |
| 5439938 | Snyder et al. | Aug 1995 | A |
| 5476852 | Cauwenbergh | Dec 1995 | A |
| 5505958 | Bello et al. | Apr 1996 | A |
| 5538740 | Abad | Jul 1996 | A |
| 5543430 | Kaesemeyer | Aug 1996 | A |
| 5576351 | Yoshimura et al. | Nov 1996 | A |
| 5595753 | Hechtman | Jan 1997 | A |
| 5629002 | Weuffen et al. | May 1997 | A |
| 5632981 | Saavedra et al. | May 1997 | A |
| 5648101 | Tawashi | Jul 1997 | A |
| 5691423 | Smith et al. | Nov 1997 | A |
| 5698738 | Garfield et al. | Dec 1997 | A |
| 5714472 | Gray et al. | Feb 1998 | A |
| 5762963 | Byas-Smith | Jun 1998 | A |
| 5789442 | Garfield et al. | Aug 1998 | A |
| 5853768 | Altadonna | Dec 1998 | A |
| 5891459 | Cooke et al. | Apr 1999 | A |
| 5895658 | Fossel | Apr 1999 | A |
| 5922332 | Fossel | Jul 1999 | A |
| 5925372 | Berner et al. | Jul 1999 | A |
| 5939094 | Durif et al. | Aug 1999 | A |
| 6036977 | Drizen et al. | Mar 2000 | A |
| 6103275 | Seitz et al. | Aug 2000 | A |
| 6117872 | Maxwell et al. | Sep 2000 | A |
| 6207713 | Fossel | Mar 2001 | B1 |
| 6242229 | Pineau | Jun 2001 | B1 |
| 6375672 | Aksan et al. | Apr 2002 | B1 |
| 6387081 | Cooper | May 2002 | B1 |
| 6448267 | Anggard et al. | Sep 2002 | B1 |
| 6451337 | Smith et al. | Sep 2002 | B1 |
| 6458841 | Fossel | Oct 2002 | B2 |
| 6511991 | Hrabie et al. | Jan 2003 | B2 |
| 6538033 | Bing | Mar 2003 | B2 |
| 6617337 | Wilcox | Sep 2003 | B1 |
| 6716436 | Seguin | Apr 2004 | B1 |
| 6747063 | Adams et al. | Jun 2004 | B2 |
| 20020015713 | Murdock et al. | Feb 2002 | A1 |
| 20020037854 | Breton et al. | Mar 2002 | A1 |
| 20020168325 | Lerner et al. | Nov 2002 | A1 |
| 20020168424 | Shahinpoor et al. | Nov 2002 | A1 |
| Number | Date | Country |
|---|---|---|
| 10128910 | Dec 2002 | DE |
| 0338291 | Oct 1989 | EP |
| 0391342 | Oct 1990 | EP |
| 1210933 | Jun 2002 | EP |
| 1553063 | Nov 1967 | FR |
| 5940 | Apr 1968 | FR |
| 2602678 | Feb 1988 | FR |
| 2740453 | Apr 1997 | FR |
| 2810540 | Dec 2001 | FR |
| 2094142 | Sep 1982 | GB |
| 04-005231 | Sep 1992 | JP |
| 6-247832 | Sep 1994 | JP |
| 7-53336 | Feb 1995 | JP |
| 09241156 | Sep 1997 | JP |
| WO 8806034 | Aug 1988 | WO |
| WO 9208705 | May 1992 | WO |
| WO 9409750 | May 1994 | WO |
| WO 9513060 | May 1995 | WO |
| 9515147 | Jun 1995 | WO |
| WO 9515147 | Jun 1995 | WO |
| WO 9608966 | Sep 1995 | WO |
| WO 9614748 | May 1996 | WO |
| WO 9629988 | Oct 1996 | WO |
| WO 9716983 | May 1997 | WO |
| WO 9739760 | Oct 1997 | WO |
| WO 9913717 | Mar 1999 | WO |
| WO 0003689 | Jan 2000 | WO |
| WO 0040215 | Jul 2000 | WO |
| WO 0054773 | Sep 2000 | WO |
| WO 0069469 | Nov 2000 | WO |
| WO 0145713 | Jun 2001 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20030028169 A1 | Feb 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 08932227 | Sep 1997 | US |
| Child | 10201635 | US |
